- Home
- CRC vs GH Comparison
CRC vs GH Comparison
Compare CRC & GH Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- CRC
- GH
- Stock Information
- Founded
- CRC 2014
- GH 2011
- Country
- CRC United States
- GH United States
- Employees
- CRC N/A
- GH N/A
- Industry
- CRC Oil & Gas Production
- GH Medical Specialities
- Sector
- CRC Energy
- GH Health Care
- Exchange
- CRC Nasdaq
- GH Nasdaq
- Market Cap
- CRC 4.1B
- GH 4.9B
- IPO Year
- CRC N/A
- GH 2018
- Fundamental
- Price
- CRC $48.01
- GH $50.15
- Analyst Decision
- CRC Strong Buy
- GH Strong Buy
- Analyst Count
- CRC 11
- GH 20
- Target Price
- CRC $61.27
- GH $54.35
- AVG Volume (30 Days)
- CRC 951.6K
- GH 2.0M
- Earning Date
- CRC 08-05-2025
- GH 08-06-2025
- Dividend Yield
- CRC 3.21%
- GH N/A
- EPS Growth
- CRC 61.94
- GH N/A
- EPS
- CRC 5.76
- GH N/A
- Revenue
- CRC $3,312,000,000.00
- GH $773,996,000.00
- Revenue This Year
- CRC $12.21
- GH $23.14
- Revenue Next Year
- CRC N/A
- GH $21.42
- P/E Ratio
- CRC $8.31
- GH N/A
- Revenue Growth
- CRC 43.01
- GH 28.20
- 52 Week Low
- CRC $30.97
- GH $20.14
- 52 Week High
- CRC $60.41
- GH $53.42
- Technical
- Relative Strength Index (RSI)
- CRC 61.85
- GH 56.81
- Support Level
- CRC $46.96
- GH $48.90
- Resistance Level
- CRC $48.30
- GH $52.46
- Average True Range (ATR)
- CRC 1.14
- GH 1.97
- MACD
- CRC 0.00
- GH -0.23
- Stochastic Oscillator
- CRC 79.62
- GH 48.74
About CRC California Resources Corporation
California Resources Corp is an independent oil and natural gas exploration and production company operating properties exclusively within California. It provides affordable and reliable energy in a safe and responsible manner, to support and enhance the quality of life of Californians and the local communities in which the company operates. It has some of the lowest carbon intensity production in the United States and is focused on maximizing the value of its land, mineral, and technical resources for decarbonization by developing carbon capture and storage (CCS) and other emissions-reducing projects.
About GH Guardant Health Inc.
Guardant Health, Inc, based in Redwood City, California, is a leader in liquid-based cancer tests for clinical and research use. The company offers Guardant360 LDT, a liquid biopsy test for treatment selection in advanced stage cancer, Guardant360 CDx, an FDA-approved companion diagnostic for several targeted therapies, and Guardant OMNI, a broader gene panel for immuno-oncology research. In 2021, Guardant launched Reveal, a tumor-agnostic molecular residual disease, or MRD, test. In 2024, the company received US FDA approval for Shield, a liquid biopsy for colorectal cancer, or CRC, screening. Additionally, Guardant offers research development services such as regulatory approval consultancy and clinical trial referrals.